Awakn Life Sciences
Awakn Life Sciences is a publicly listed Canadian clinical services company that operates ketamine-assisted psychotherapy clinics, most notably Awakn Clinics Oslo AS in Norway, treating patients with treatment-resistant depression and related mental health conditions.
- Company typePrivate
- Founded2020
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Awakn Life Sciences does
Awakn Life Sciences is a Toronto-headquartered, publicly listed (otcqb:AWKNF) clinical services company that operates and develops ketamine-assisted psychotherapy clinics for patients with treatment-resistant mental health conditions, notably treatment-resistant depression. Founded in 2020 with a disclosed headcount of 1-10 employees, the company combines ketamine administration with psychotherapy delivered by qualified physicians, using proprietary clinical protocols as its core differentiator.
The company's commercial footprint is anchored by Awakn Clinics Oslo AS, launched in October 2021 through the acquisition of Norway-based Axonklinikken AS, which serves as its platform for Nordic and broader European expansion. The acquisition consideration was structured as a combination of share issuance and milestone-based payments, and the clinic is led by Dr. Lowan Stewart. The company's stated go-to-market is direct-to-patient via owned clinic facilities, with revenue generated from professional services (clinical treatment delivery) rather than product sales. Marketing and pricing models are not publicly disclosed.
Between 2021 and 2024, Awakn raised approximately $12.7M across multiple rounds, with the largest being a $6.85M Negev Capital-led round in June 2021 and subsequent smaller raises from Mystic Ventures (2023), the National Institute for Health and Care Research (2022), and TD Veen (2022). Leadership includes Dennis Purcell (CEO), Anthony Tennyson (CEO and co-founder), Jonathan Held (co-founder and CFO), and Shaun McNulty (CSO). The company operates within the global ketamine clinics market, projected at USD 2.6B in 2025 and USD 8.1B by 2034 at a 13.5% CAGR, with North America holding 46.5% and Europe 25.0% revenue share.
Awakn Life Sciences firmographics
Firmographics- Name
- Awakn Life Sciences
- Website
- https://awaknlifesciences.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Awakn Life Sciences is a publicly listed Canadian clinical services company that operates ketamine-assisted psychotherapy clinics, most notably Awakn Clinics Oslo AS in Norway, treating patients with treatment-resistant depression and related mental health conditions.
- Ownership category
- akta.pro rank
Awakn Life Sciences industry classification
Industry- Product category
- Mental Health Services
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Behavioral Health Benefit Administration (MBHO Core) (HLAEAHAA)
Keywords
Where Awakn Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Awakn Life Sciences business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Services Revenue: Revenue generated from providing ketamine-assisted psychotherapy treatments to patients at clinic locations. The acquisition structure includes both share issuance and milestone-based payments.
Go-to-market motion2 records
Distribution channels1 record
Awakn Life Sciences product offering
Product offeringCore offering
Awakn Life Sciences operates specialized clinical facilities that deliver ketamine-assisted psychotherapy to patients suffering from treatment-resistant depression, addiction, and other mental health conditions. The company's core service combines ketamine administration with structured psychotherapy sessions conducted by qualified physicians, including Dr. Lowan Stewart who leads clinic operations in Norway. Awakn has expanded its clinical footprint from the UK into the Nordic region through the 2021 acquisition of Norwegian ketamine clinic Axonklinikken AS, which was rebranded as Awakn Clinics Oslo AS.
Product overview
Awakn Life Sciences is a biotechnology company focused on developing and delivering psychedelic-assisted therapies for mental health conditions. The company operates ketamine-assisted psychotherapy clinics, having expanded into the Nordic region through the acquisition of Axonklinikken AS in Norway (2021). The company provides clinical treatment services for conditions such as addiction and treatment-resistant depression using ketamine-assisted psychotherapy protocols.
Differentiator
Problem solved
Functional benefit
Products and services
- Awakn Clinics Oslo AS Wholly-owned ketamine-assisted psychotherapy clinic in Oslo, Norway, launched as part of Awakn's Nordic region expansion following the acquisition of Axonklinikken AS in 2021. Provides ketamine-assisted psychotherapy to patients with treatment-resistant mental health conditions.
- Ketamine-Assisted Psychotherapy Treatment Core clinical service combining ketamine administration with psychotherapy sessions delivered by qualified physicians for patients with treatment-resistant depression, addiction, and other mental health conditions. Offered across Awakn's owned clinic network in the UK and Norway.
Quantifiable outcome
- Expansion into Nordic market completed via acquisition of existing ketamine clinic
Companies that use Awakn Life Sciences
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Awakn Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Awakn Life Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Axonklinikken AScoreAcquisition of Axonklinikken AS, a ketamine-assisted psychotherapy clinic in Norway, as part of Awakn's expansion into the Nordic region. The deal includes issuing shares and milestone-based payments. Dr. Lowan Stewart, a leading ketamine physician, leads the new clinic operations.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Awakn Life Sciences competitors and assessment
Company assessmentDirect peers
- Field Trip Health: Operated ketamine-assisted psychotherapy clinics for mental health conditions (including treatment-resistant depression) across North America and Europe. Closely comparable specialty clinic model targeting the same patient population with ketamine-based treatment protocols.
- Novamind (now subsidiary of Aurora Cannabis): Ran a network of outpatient mental health and ketamine clinics offering psychedelic-assisted psychotherapy. Direct competitor in the ketamine clinic space with a similar specialty outpatient model.
- Greenbrook TMS: Operates a national network of outpatient mental health clinics offering TMS and related neuromodulation therapies for depression. Comparable specialty outpatient clinic model targeting treatment-resistant depression patients.
- Delic Holdings (formerly Field Trip Health): Holding company focused on psychedelic wellness and ketamine clinics following the rebranding of Field Trip Health assets. Direct successor competitor in the ketamine-assisted psychotherapy clinic market.
Broad incumbents
- Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Comparable in therapeutic focus (TRD, novel mechanisms) but operating in clinical trials rather than clinic delivery.
- MindMed: Clinical-stage psychedelic medicine company developing LSD and MDMA-based therapies for mental health. Comparable in psychedelic-assisted therapy focus and target indications (anxiety, depression, addiction) but operates in drug development rather than clinic services.
- Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and other novel therapies for mental health conditions including depression and addiction. Comparable in psychedelic therapy pipeline targeting similar indications.
Emerging players
- Cerebral: Telehealth mental health platform offering medication management and therapy for depression and anxiety. Comparable in targeting mental health patients seeking alternative treatments, though delivered virtually rather than in-person.
- Bicycle Health: Virtual opioid use disorder treatment provider offering medication-assisted treatment via telemedicine. Comparable in novel mental health/addiction treatment delivery and direct-to-patient model, focused on addiction.
- Talkiatry: Telepsychiatry practice providing psychiatric evaluation, medication management, and therapy. Comparable in mental health medication management focus and outpatient delivery model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Awakn Life Sciences social profiles
Digital presenceAwakn Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Awakn Life Sciences leadership team
Management profileNumber of profiles
Profiles5 records
Awakn Life Sciences subsidiaries and ownership
Company hierarchySubsidiaries2 records
Awakn Life Sciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Awakn Life Sciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Awakn Life Sciences
What does Awakn Life Sciences do?
Awakn Life Sciences operates specialized clinical facilities that deliver ketamine-assisted psychotherapy to patients suffering from treatment-resistant depression, addiction, and other mental health conditions. The company's core service combines ketamine administration with structured psychotherapy sessions conducted by qualified physicians, including Dr. Lowan Stewart who leads clinic operations in Norway. Awakn has expanded its clinical footprint from the UK into the Nordic region through the 2021 acquisition of Norwegian ketamine clinic Axonklinikken AS, which was rebranded as Awakn Clinics Oslo AS.
Is Awakn Life Sciences a public or private company?
Awakn Life Sciences is a private company. It is classified as public and is currently operating.
When was Awakn Life Sciences founded?
Awakn Life Sciences was founded in 2020. It employs 1 to 10 people.
Where is Awakn Life Sciences based?
Awakn Life Sciences is headquartered in Toronto, Canada, in the North America region.
How does Awakn Life Sciences make money?
One revenue line is on record: clinical Services Revenue.
Who are Awakn Life Sciences's main competitors?
Direct peers on record are Field Trip Health, Novamind (now subsidiary of Aurora Cannabis), Greenbrook TMS and Delic Holdings (formerly Field Trip Health). Broad incumbents are Compass Pathways, MindMed and Atai Life Sciences. Emerging players are Cerebral, Bicycle Health and Talkiatry.
Does Awakn Life Sciences have an API?
No public API is recorded for Awakn Life Sciences.
What industry is Awakn Life Sciences in?
Awakn Life Sciences's product category is Mental Health Services. Its primary akta.pro industry code is HLAEAHAA, Behavioral Health Benefit Administration (MBHO Core). Its NAICS code is 621420 and its SIC code is 8093.